



MYDECINE

MEDICINE EVOLVED

MYDECINE INNOVATIONS GROUP ANNOUNCES ISSUANCE OF RESTRICTED STOCK UNITS TO KEY PERSONNEL

DENVER, November 30, 2021 – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (“**Mydecine**” or the “**Company**”), is pleased to announce that on November 25, 2021 the Company issued certain Restricted Stock Units (“**RSUs**”) in order to recognize the past contributions of certain of its key management personnel who have been instrumental in advancing the best interests of the Company forward by providing services to the Company in excess of the usual and ordinary services expected or required of such personnel.

The RSUs were issued pursuant to the terms of the Company's Equity Incentive Plan which received approval of the shareholders of the Company at its annual general and special meeting of shareholders held September 20, 2021. Under the Company's Equity Incentive Plan, RSUs are issued as an unfunded and unsecured promise to deliver common shares in the capital of the Company (each a “**Common Share**” and collectively, the “**Common Shares**”), cash, other securities or other property, subject to certain restrictions and in accordance with the provisions of the Equity incentive Plan.

The Company issued an aggregate of 15,896,116 RSUs to the following individuals in the amounts set forth opposite their name:

David Joshua Bartch	5,298,940
Robert Roscow	4,666,585
Damon Michaels	4,494,125
Larry Dean Ditto Jr.	779,259
Dr. Rakesh Jetly	338,853
Sanford M. Stein	318,354
TOTAL:	15,896,116

The Fair Market Value of the RSUs issued above was deemed to be the closing price of underlying securities of such RSUs, being the Common Shares, on the trading day prior to the date of grant of the RSUs, being \$0.195 per Common Share. The RSUs were issued with an immediate vesting period such that the RSUs were issued to the foregoing persons as Common Shares effective November 25, 2021. These RSUs were intended to be formally granted after the establishment of the Equity Incentive Plan in August 2021 as incentive for management to complete the Company's spinout of its U.S. cannabis assets (the “**Spinout**”), which was completed in October 2021. Such grants, however, were delayed due to administrative reasons and, therefore, the Company determined it is advisable to grant the RSUs with an immediate vesting schedule to equitably reward management's efforts in connection with the Spinout.

On behalf of the Board of Directors:

“David Joshua Bartch”

David Joshua Bartch, Chief Executive Officer

For more information:

Media Contact

Courtney Ryan
LS2group
cryan@ls2group.com
515-770-4823

Investor Contacts

Charles Lee, Investor Relations
corp@mydecineinc.com
1-720-277-9879

Allison Soss / Erika Kay
KCSA Strategic Communications
myco@kcsa.com
1-212-896-1267

About Mydecine Innovations Group

Mydecine Innovations Group (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) is an emerging biotech and life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing vitality. The company’s world-renowned medical and scientific advisory board is building out a robust R&D pipeline of nature-sourced psychedelic-assisted therapeutics, novel compounds, therapy protocols, and unique delivery systems. Mydecine has exclusive access to a full cGMP certified pharmaceutical manufacturing facility with the ability to import/export, cultivate, extract/isolate, and analyze active mushroom compounds with full government approval through Health Canada. Mydecine also operates out of a state-of-the-art mycology lab in Denver, CO to focus on genetic research for scaling commercial cultivation of rare (non-psychedelic) medicinal mushrooms.

Learn more at: <https://www.mydecine.com/> and follow us on [Facebook](#), [Twitter](#), and [Instagram](#).

Forward-Looking Statements

This news release contains forward-looking information within the meaning of Canadian securities laws regarding the Company and its business, which relate to future events or future performance and reflect management’s current expectations and assumptions. Often but not always, forward-looking information can be identified by the use of words such as “expect”, “intends”, “anticipated”, “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would” or “will” be taken, occur or be achieved. Forward looking-

information in this news release includes, but is not limited to: statements with respect to completion of the Arrangement; benefits of the Arrangement; and timing of closing of the Arrangement. Such forward-looking statements reflect management's current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, without limitation, risks regarding the COVID-19 pandemic, the availability and continuity of financing, the ability of the Company to adequately protect and enforce its intellectual property, the Company's ability to bring its products to commercial production, continued growth of the global adaptive pathway medicine, natural health products and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale and use of the Company's products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation.